NASDAQ:SPTX Seaport Therapeutics Q3 2026 Earnings Results & Report $20.01 +0.41 (+2.09%) As of 04:00 PM Eastern Seaport Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 2, 2026. The company reported EPS of -$0.49 versus the -$0.58 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 2, 2026TimeBefore Market OpensConference Call7:00 AM ET Seaport Therapeutics EPS ResultsActual EPS-$0.49Consensus EPS -$0.58Beat/MissBeat by +$0.09One Year Ago EPSN/ASeaport Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Seaport Therapeutics Q3 2026 Earnings FAQ Did Seaport Therapeutics beat earnings estimates for Q3 2026? Seaport Therapeutics (NASDAQ:SPTX) reported earnings of -$0.49 per share for Q3 2026, beating the consensus estimate of -$0.58. The report was announced on Monday, November 2, 2026. Seaport Therapeutics Earnings HeadlinesSeaport Therapeutics Reports Positive GlyphAllo Data; GlyphAgo Phase 2a Trial UnderwayNovember 2 at 4:28 PM | rttnews.comSeaport Therapeutics reports Q3 EPS (49c), consensus (56c)November 2 at 4:28 PM | tipranks.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.November 2 at 1:00 AM | Decentralized Masters (Ad)Seaport Therapeutics' Q3 Net Loss NarrowsNovember 2 at 4:28 PM | finance.yahoo.comSeaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressNovember 2 at 4:28 PM | finance.yahoo.comSPTX - Seaport Therapeutics, Inc.October 31 at 3:27 AM | seekingalpha.comSee More Seaport Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Seaport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seaport Therapeutics and other key companies, straight to your email. Email Address About Seaport TherapeuticsSeaport Therapeutics (NASDAQ:SPTX) is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain. Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care. The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts. Seaport Therapeutics is conducting clinical development activities in the United States and operates as a biotechnology company focused primarily on advancing its proprietary pipeline rather than marketing commercially approved products.View Seaport Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation Reset Upcoming Earnings Booking (11/3/2026)Ferrari (11/3/2026)Marathon Petroleum (11/3/2026)Mplx (11/3/2026)Suncor Energy (11/3/2026)Apollo Global Management (11/3/2026)Itau Unibanco (11/3/2026)Amgen (11/3/2026)Pfizer (11/3/2026)Eaton (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
